Matthew M Behymer
Overview
Explore the profile of Matthew M Behymer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behymer M, Mo H, Fujii N, Suresh V, Arzumanian A, Chan A, et al.
Toxicol Sci
. 2023 Nov;
PMID: 37952247
Cyanide represents a persistent threat for accidental or malicious misuse due to easy conversion into a toxic gas and access to large quantities through several industries. The high safety index...
2.
Bebarta V, Shi X, Zheng S, Hendry-Hofer T, Severance C, Behymer M, et al.
Toxicol Sci
. 2022 Nov;
191(1):90-105.
PMID: 36326479
Cyanide-a fast-acting poison-is easy to obtain given its widespread use in manufacturing industries. It is a high-threat chemical agent that poses a risk of occupational exposure in addition to being...
3.
Behymer M, Mo H, Fujii N, Suresh V, Chan A, Lee J, et al.
Chem Res Toxicol
. 2022 Oct;
35(11):1983-1996.
PMID: 36201358
The development of rapidly acting cyanide countermeasures using intramuscular injection (IM) represents an unmet medical need to mitigate toxicant exposures in mass casualty settings. Previous work established that cisplatin and...
4.
Wang J, Toregrosa-Allen S, Elzey B, Utturkar S, Lanman N, Bernal-Crespo V, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(45).
PMID: 34740973
Tumor antigen heterogeneity, a severely immunosuppressive tumor microenvironment (TME) and lymphopenia resulting in inadequate immune intratumoral trafficking, have rendered glioblastoma (GBM) highly resistant to therapy. To address these obstacles, here...